Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2024-05-13 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于股东无偿捐赠部分公司股份的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding a shareholder's donation of company shares to a charitable foundation. It details the donation plan, the parties involved, the number and percentage of shares donated, and the intended use of proceeds from the sale of these shares. The document also includes information about the subsequent sale plan of the donated shares by the foundation. There is no financial data, earnings information, or management discussion of financial results. The document is a formal announcement about a share donation and related share sale plan, which fits the category of a Share Issue/Capital Change announcement, as it involves a change in share ownership and capital structure through donation and sale. The document length is 4155 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-05-13 Chinese
关于股东无偿捐赠部分公司股份完成过户的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a non-trade transfer of shares as a donation from a shareholder to an educational foundation. It details the shareholding changes before and after the donation, confirms no change in control or governance, and includes references to regulatory filings and confirmations. The document is short (1197 characters) and focuses on a specific shareholding transaction rather than financial results or management discussion. It does not contain financial statements or earnings data, nor is it a report or presentation. This fits the category of a Major Shareholding Notification (MRQ), as it reports a significant change in share ownership levels due to the donation of shares.
2024-05-07 Chinese
关于控股股东部分股份质押及解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, released, and the related procedures completed. The content focuses on share pledging activities and does not contain financial statements, earnings data, or management discussion. It is a regulatory announcement about share pledging status, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is a formal disclosure of share pledge status, typical of RNS filings in Chinese markets.
2024-05-05 Chinese
北京市金杜（深圳）律师事务所关于深圳信立泰药业股份有限公司2023年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2023 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the legal compliance of the AGM's convening, attendance, voting procedures, and results. The document does not contain the actual annual report or financial statements but rather focuses on the legality and procedural correctness of the AGM. It is not a report publication announcement since it is a substantive legal opinion on the AGM itself. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related legal opinions about the AGM.
2024-04-22 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司2024 年第一季度报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including income, profit, assets, liabilities, and equity for the first quarter of 2024. The document includes consolidated balance sheets, profit statements, and detailed notes on financial performance and shareholder information. It explicitly states it is a quarterly report and includes substantive financial statements and analysis for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-22 Chinese
关于增资子公司Salubris Biotherapeutics, Inc.的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding an increase in capital investment in its subsidiary Salubris Biotherapeutics, Inc. It details the investment amount, the ownership structure before and after the investment, the business and financial status of the subsidiary, the board resolution approving the investment, and the purpose and risks associated with the investment. The document is a formal disclosure of a capital increase transaction involving a subsidiary, including financial data and corporate governance approvals. It is not a full financial report, earnings release, or management discussion, but rather a specific update on financing activity related to capital injection. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 4927 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-04-22 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.